Literature DB >> 2057974

Antiphospholipid antibodies in cerebral ischemia.

J Montalbán1, A Codina, J Ordi, M Vilardell, M A Khamashta, G R Hughes.   

Abstract

In a 2-year prospective study of 146 patients with cerebral ischemia, we compared vascular risk factors for stroke with clinical and laboratory findings, particularly antiphospholipid antibodies. Ten patients (6.8%) were positive for at least one antiphospholipid antibody; one patient had systemic lupus erythematosus, one had rheumatoid arthritis, and the remaining eight fulfilled criteria for the diagnosis of primary antiphospholipid syndrome. These patients were predominantly male, not necessarily young, and 50% of them did not have any other vascular risk factors; there were no significant clinical or paraclinical differences between these patients and those without antiphospholipid antibodies. Outcome in the 10 patients was good, and platelet antiaggregating drugs proved to be useful in preventing further cerebrovascular ischemic events in our patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2057974     DOI: 10.1161/01.str.22.6.750

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

Review 1.  Identification and management of difficult stroke and TIA syndromes.

Authors:  M M Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

Review 2.  Is there an increased risk of stroke associated with oral contraceptives?

Authors:  K Zeitoun; B R Carr
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

3.  Cost-effective investigation of patients with suspected transient ischaemic attacks.

Authors:  G J Hankey; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Recognizing antiphospholipid syndrome. Case report: misdiagnosis delayed treatment.

Authors:  P Kirk; J A Moran
Journal:  Can Fam Physician       Date:  1996-02       Impact factor: 3.275

Review 5.  Neurologic manifestations of the antiphospholipid syndrome.

Authors:  D Tanne; S Hassin-Baer
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 6.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

7.  Antiphospholipid syndrome.

Authors:  M Khamashta; G R Hughes
Journal:  BMJ       Date:  1993-10-09

8.  Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.

Authors:  E Zuckerman; E Toubi; T D Golan; T Rosenvald-Zuckerman; E Sabo; Z Shmuel; D Yeshurun
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

Review 9.  The antiphospholipid syndrome.

Authors:  G R Hughes; M A Khamashta
Journal:  J R Coll Physicians Lond       Date:  1994 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.